The precise timeline based on clinical trial tracking: Weeks 1-3: Mild symptoms beginning, most patients adapting to medication Weeks 4-8: Peak side effect period highest nausea, GI symptoms at their worst Weeks 9-12: Rapid improvement, most GI symptoms resolving Weeks 13-24: Minimal symptoms for most, discontinuation rate drops to under 2% Weeks 25-48: Essentially no side effects for 85%+, focus shifts to weight maintenance According to research published in the New England Journal of Medicine on GLP-1 agonists, this pattern is consistent across the entire class of incretin-based therapies
Its your journey and Daytryp is here to make it as easy and effective as possible
Phillips 7 1 Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
For those with neuropsychiatric symptoms from low B12, these findings offer hope and a clear path to getting better